If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
==== 14 March ==== Following the secession of Slovakia and Ruthenia, British Ambassador to Czechoslovakia Basil Newton advised President Hácha to meet with Hitler. When Hácha arrived in Berlin on 14 March, he met with the German Foreign Minister, Joachim von Ribbentrop prior to meeting with Hitler. Von Ribbentrop testified at the Nuremberg trials that during this meeting, Hácha had told him that "he wanted to place the fate of the Czech State in the Führer's hands." Hácha later met with Hitler, where Hitler gave the Czech President two options: cooperate with Germany, in which case the "entry of German troops would take place in a tolerable manner" and "permit Czechoslovakia a generous life of her own, autonomy and a degree of national freedom..." or face a scenario in which "resistance would be broken by force of arms, using all means." Minutes of the conversation noted that for Hácha this was the most difficult decision of his life but believed that in only a few years this decision would be comprehensible and in 50 years would probably be regarded as a blessing. After the negotiations had finished, Hitler told his secretaries, "It is the greatest triumph of my life! I shall enter history as the greatest German of them all." According to Joachim Fest, Hácha suffered a heart attack induced by Hermann Göring's threat to bomb the capital and by four o'clock he contacted Prague, effectively "signing Czechoslovakia away" to Germany.
The Jackson Labs DO (Diversity Outbred) project is a mouse breeding program using multiple inbred founder strains to create a genetically diverse population of mice for use in scientific research. These mice are designed for fine genetic mapping, and capture a large portion of the genetic diversity of the mouse genome. This project has resulted in over 1,000 genetically diverse mice which have been used to identify genetic factors for diseases such as obesity, cancer, diabetes, and alcohol use disorder.
Furthermore, specific LTBP isoforms have a propensity to associate with specific LAP•TGF-β isoforms. For example, LTBP-4 is reported to bind only to TGF-β1, thus, mutation in LTBP-4 can lead to TGF-β associated complications which are specific to tissues that predominantly involves TGF-β1. Moreover, the structural differences within the LAP's provide different latent TGF-β complexes which are selective but to specific stimuli generated by specific activators.
== Works cited == Bertok L, Chow D (2005). Bertok L, Chow D (eds.). Natural Immunity. Vol. 5 (1st ed.). Elsevier Science. ISBN 978-0-44451-755-5. Breinstrup, Thomas (2006). "Un revolution in le mundo scientific" [A revolution in the scientific world]. Historia de interlingua (in Interlingua). Archived from the original on 2019-04-27. Retrieved 2025-01-14. Chung, Kyung Won (2005). Gross Anatomy (Board Review). Lippincott Williams & Wilkins. ISBN 0-7817-5309-0. Cook, Chad E. (2012). Orthopedic Manual Therapy: An Evidence Based Approach (2nd ed.). Upper Saddle River, NJ: Pearson Education. ISBN 978-0-13-802173-3. Breinstrup, Th.; Stenström, Ingvar; Olsson, Jesper, eds. (2007) [2001]. "Biographias: Ingvar Stenström". Interlingua (in Interlingua). Archived from the original on 2019-04-26. Retrieved 2025-01-15. Dinour, Lauren M. (2019). "Speaking Out on 'Breastfeeding' Terminology: Recommendations for Gender-Inclusive Language in Research and Reporting". Breastfeeding Medicine. 14 (8). Mary Ann Liebert: 523–532. doi:10.1089/bfm.2019.0110. PMID 31364867. Fielding, Lucie (2021). Trans Sex: Clinical Approaches to Trans Sexualities and Erotic Embodiments. New York: Routledge. ISBN 978-0-429-31829-0. Edwards, Heather. "Anatomy Talk". pp. 165–168. Gopsill, Frank Peter (1990). International languages: a matter for Interlingua. Sheffield, England: British Interlingua Society. ISBN 0-9511695-6-4. OCLC 27813762. Gopsill, Frank Peter (1994). Interlingua today: A course for beginners. Sheffield, England: British Interlingua Society. ISBN 978-1-898017-01-1.
=== Preventing diabetes mellitus type 1 === Currently, there is no known way to prevent diabetes mellitus type 1. However, onset of diabetes mellitus type 1 may be delayed by about two years by administering Teplizumab.
Sources: en.wikipedia.org
== Background == High performance liquid chromatography (HPLC) and electron ionization mass spectrometry (EIMS) are two analytical techniques that, in principle, seem to be incompatible. However, because these two approaches share a great deal of applications in the analysis of suitable molecules, typically less than 1000 u, a large effort has been devoted by the scientific community to develop a reliable, easy-to-use, and flawless interface. The first successful and commercially available device to combine EI and HPLC was designed by Willoughby and Browner in 1984. It was based on the conversion of the solute into a beam of particles, after the formation of spray droplets and the elimination of the solvent vapors through a multi-stage momentum separator. Although its efficient interfacing mechanism and a unique trait, particle beam performance was sometimes inadequate to an increasing number of new, demanding applications and was quickly replaced by a family of atmospheric pressure ionization-based interfaces (API) when they became commercially available. However, the possibility to record an EI spectrum from an HPLC application remained a challenge for a long time. The first Direct-EI prototype was first presented in 2002 and proposed an innovative approach that improved interfacing performance compared to that of particle beam and opened new opportunities for LC-MS applications.
=== Loose connective tissue === Loose connective tissue contains fibers, extracellular matrix, cells, nerves and blood vessels. The extracellular compartment consists of Type 1, 3, and 5 collagen fibers bundles embedded in intercellular substance. The PDL collagen fibers are categorized according to their orientation and location along the tooth. The cells include fibroblast, defence cells and undifferentiated mesenchymal cells.
Stanozolol and other synthetic steroids were first banned by the International Olympic Committee and the International Association of Athletics Federations in 1974, after methods to detect them had been developed. There are many known cases of doping in sports with stanozolol by professional athletes. Stanozolol is especially widely used by the athletes from post-Soviet countries. As of 2015, it is banned by World Anti-Doping Agency and United States Anti-Doping Agency.
27 April An estimated battalion of PAVN assaulted a night defensive position of a unit of the 2nd Brigade, 25th Infantry Division 10 km northeast of Trảng Bàng. The attack was repulsed with 100 PAVN/VC killed and one captured and 32 individual and 23 crew-served weapons captured; U.S. losses were ten killed. A grass fire spread to the Marines/Navy ammunition supply point 1 near Hill 327 causing a massive explosion and fire.
== Funding == ICICI Venture invested 35 crore in Metropolis in the year 2006 through its India Advantage Fund. In 2010, Warburg Pincus invested about $85 Million in Metropolis, paving a way for ICICI to exit. The Shah family purchased the exiting stake from Warburg Pincus for a healthy return on investment. The company is backed by several investors including Carlyle Group, CA Lotus Investments and Kohlberg Kravis Roberts (KKR). In 2015, KKR backed Ameera Shah through ₹5.6 billion (equivalent to ₹9.2 billion or US$96 million in 2026) promoter debt funding. In April 2019, the company raised Rs 530 crore from 26 anchor investors, including Small Cap World Fund, Neuberger Berman Emerging Market Equity Fund, Fundsmith Emerging Equities Trust PLC and First State Indian Sub Continent Fund, among others.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.